University Hospital Erlangen

This phase 3 trial tested a personalized vaccine made from a patient's own immune cells and tumor RNA in 200 people with a high-risk form of eye cancer (uveal melanoma with monosomy 3). After surgery to remove the tumor, half received the vaccine over two years and half were simp…